CEVEC Raises €6M to Grow CAP Technology Based Protein and Vaccine Business
CEVEC Pharmaceuticals, licensing its human CAP® Technology based expression system for proteins and vaccines, announced the closing of a €6M financing round. NRW.BANK and Creathor Venture Fonds led this round which included the participation from current investors, a group of private and institutional investors and ERP Startfonds of KfW bank. The funding enables CEVEC to strengthen the growth of its protein and vaccine commercialization business of the proprietary CAP® Technology platform. CEVEC also intends to develop certain vaccines together with partners based on a further financing round, to be closed by the end of 2011.
The CAP ® Technology platform comprises human CAP® and CAP-T™ expression systems and is used for the manufacture of complex biologics and therapeutic antibodies with human-like glycosylation and sialylation patterns. New data proved that the human CAP ® technology is also an excellent platform for various vaccine production needs. Outstanding data obtained with the only independent available human cell system for various influenza strains and various other vaccine types show the broad range where the CAP system can be used.
Other news from the department business & finance
